OptiBiotix Health PLC ProBiotix Health - Appointment of CEO
20 Giugno 2022 - 8:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
20 June 2022
20 June 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company")
ProBiotix Health - Appointment of Chief Executive Officer
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, notes the announcement (14 June 2022) by ProBiotix
Health plc (AQSE: PBX) ("ProBiotix Health"), that Steen Andersen
("Steen") has been appointed as Chief Executive Officer ("CEO"),
and that Steen will join the company after completing his notice
period with his current employer. The Company has a 44 per cent.
shareholding in ProBiotix Health.
This is part of a long-planned strategy by OptiBiotix and its
portfolio companies (the "Group") to appoint experienced industry
commercial leaders to each part of the business allowing the Group
CEO to focus on identifying, developing and acquiring the new
technologies or companies that will provide the Group with a
pipeline of products and applications to deliver future growth and
market value. This structure gives shareholders exposure to
multiple opportunities within the emerging microbiome space and
affords the potential to deliver additional value through separate
public listing of the businesses and dividend return as achieved
with the listing of ProBiotix Health earlier in the year.
Stephen O'Hara, CEO of OptiBiotix, commented: "The appointment
of Steen as CEO of ProBiotix Health will help accelerate the growth
and recognition of the business into its next phase of evolution.
Having established international sales and brand awareness of its
award winning LP(LDL) (R) probiotic as an ingredient, ProBiotix
Health is now investing in building a presence in the dairy
industry, extending the range of applications for LP(LDL) (R) into
other areas of health, and increasing access to the USA and Asian
markets."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate
Bannatyne (Corporate Finance)
Abigail Wayne (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits.
This communication is a "Reach" announcement. Reach is a
non-regulatory news service. By using this service an issuer is
confirming that the information contained in this announcement is
of a non-regulatory nature. Information required to be notified
under the AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFISREIDLIF
(END) Dow Jones Newswires
June 20, 2022 02:00 ET (06:00 GMT)
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Apr 2023 a Apr 2024
